Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Liabilities and Shareholders Equity (2019 - 2025)

Bioadaptives' Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $124360.0 for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 168.06% year-over-year to $124360.0; the TTM value through Sep 2025 reached $769208.0, up 253.18%, while the annual FY2024 figure was $261885.0, 151.82% up from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $124360.0 at Bioadaptives, down from $272515.0 in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $329302.0 in Q3 2023 and bottomed at $8735.0 in Q2 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $103998.0 (2023), against an average of $115061.2.
  • The largest annual shift saw Liabilities and Shareholders Equity tumbled 85.91% in 2024 before it skyrocketed 3019.81% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $148585.0 in 2021, then plummeted by 74.89% to $37314.0 in 2022, then surged by 178.71% to $103998.0 in 2023, then surged by 151.82% to $261885.0 in 2024, then crashed by 52.51% to $124360.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Liabilities and Shareholders Equity are $124360.0 (Q3 2025), $272515.0 (Q2 2025), and $110448.0 (Q1 2025).